KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Overweight, Obesity, and Asthma Independently Increase Expression of Inflammatory Biomarkers February 25, 2025The results of this study show that the concurrent presence of asthma and obesity did not synergistically amplify inflammation in children with both asthma and overweight/obesity.
- FDA Approves First Non-Hormonal Copper IUD in Over 40 Years February 25, 2025Miudella achieves similar efficacy to other available copper IUDs with less than half the dose of copper.
- Adiponectin to Predict Cardiometabolic Risk in Postmenopausal Women February 25, 2025Among postmenopausal women, researchers investigated the association of cardiometabolic parameters and circulating levels of visfatin, adropin, and adiponectin.
- Poor Glycemic Control for Patients With Type 2 Diabetes Increases Risk of Long COVID Symptoms February 25, 2025The increased risk of symptoms only includes respiratory-related symptoms or brain fog.
- FDA Clears Tandem’s Automated Insulin Delivery Algorithm For T2D February 25, 2025The technology will be available to patients in the United States in March 2025.
- Q&A: Advanced Practice Pharmacist on Nontraditional Roles in Health Care February 25, 2025Crystal Zhou, PharmD, APh, AHSCP, BCACP, joined Drug Topics to further discuss the Cut Hypertension Program and nontraditional roles within health care.
- The Current Dilemma in Pharmacy: Balancing Patient Satisfaction, Cost Reduction, and Safety Protocols February 25, 2025Unlock the secrets to balancing patient satisfaction, cost reduction, and safety in retail pharmacy operations. This whitepaper reveals strategies for meeting prescription promise times, managing financial pressures, and maintaining safety standards. Learn how centralized fulfillment can transform your pharmacy. Download now to optimize your operations and stay ahead in the evolving healthcare landscape.
- Symbravo Shows Greater Migraine Improvement Compared With Oral CGRP Inhibitors February 24, 2025Meloxicam and rizatriptan (Symbravo, formerly AXS-07) is a CGRP medication approved for the acute treatment of migraine with or without aura.
- Topical Medications as First-Line Treatment Options for Orofacial Pain February 24, 2025Researchers investigated the pharmacological management of chronic orofacial pain and provided guidance on its proper treatment.
- FDA Grants Emergency Authorization to Aptitude’s COVID, Flu Test February 24, 2025The next-gen molecular Metrix was given emergency use authorization for its ability to test for SARS-CoV-2 and influenza A and B viruses.
Pharmacy Times articles
- FDA OKs Label Changes for Buprenorphine Injections, Reducing Time to Treatment in Opioid Use Disorder February 25, 2025The label changes to buprenorphine extended-release injections can increase convenience and adherence for patients with moderate to severe opioid use disorder.
- Quizartinib in FLT3-ITD–Positive Acute Myeloid Leukemia: A New Era in Targeted Therapy February 25, 2025The drug solidifies its place as a first-line treatment option in AML.
- Expert: The Role of Plant-Based Protein Powders in Nutritional Supplementation February 25, 2025Phil Vigeant shares benefits and considerations of plant-based protein powders, highlighting the pharmacist's role in recommending quality plant-based protein powders.
- Study Finds Fewer Than 1% of US Clinical Trials Enroll Pregnant Participants February 25, 2025The authors note that this lack of inclusion can leave important safety and efficacy questions unanswered.
- FDA Accepts New Drug Application for Dordaviprone to Treat Recurrent H3 K27M-Mutant Diffuse Glioma February 25, 2025The designation is supported by pooled data from 4 clinical trials.
- Nadofaragene Firadenovec Shows CR and Tolerability in Patients With NMIBC February 25, 2025Nadofaragene firadenovec led to most patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer (NMIBC) experiencing a complete response (CR) at 3 months.
- Study: Certain Hormonal Contraceptives Increase Risks of Ischemic Stroke, Myocardial Infarction February 25, 2025Levonorgestrel-releasing intrauterine devices were not found to increase women’s risks of these conditions.
- Medication Is Provided Even After the Patient Reports a Drug Allergy February 25, 2025Lawsuits were initiated against the pharmacy and prescriber.
- Insight: Pharmacists Play Key Role in Educating Patients With CKD on Semaglutide Use, Management February 25, 2025According to Pranav Garimella, pharmacists are essential in counseling patients with CKD on the appropriate use of semaglutide.
- Lifileucel Approval Paves the Way for Personalized Minimally-Invasive T-Cell Therapies February 25, 2025The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at: